Discovery grant -one of the largest ever awarded for a biomedical project -to research on novel oncolytic viral strategies. Dr O'Shea's work revealed that late viral RNA export, rather than p53 inactivation, is the major determinant of ONYX-015 selectivity, an oncolytic virus that shows promise as a cancer therapy. These studies uncovered tumor cell differences in RNA export as a previously unidentified and therapeutically exploitable target. In clinical trials, many patients' tumors were found to be resistant to ONYX-015 therapy. Dr O'Shea found that heat shock, induced by febrile temperatures or drugs, rescues viral RNA export and sensitizes resistant tumor cells to ONYX-015 therapy, which has important clinical applications. Dr O'Shea has also been using viral proteins as tools with which to uncover critical cellular targets that may also be deregulated in tumor cells. Recently, she found that adenovirus encodes two viral proteins that bypass a nutrient/growth factor checkpoint for mTOR activation and protein translation, an emerging and important tumor target. She was acknowledged for this work as an Upstate Young Cell Signaler Award Finalist. Dr O'Shea's current research focuses on exploiting adenovirus as a system in which to discover how the pleiotropic perturbation of pivotal growth regulatory pathways are integrated in complex cellular networks to elicit aberrant replication, and how to uncouple them. She is using this knowledge to inform the design of rational combination drug therapies and replication-competent viruses for the treatment of cancer.
Oncogene (2005) 
